US 12,239,648 B2
KIF5B-RET fusion molecules and uses thereof
Sean R. Downing, Methuen, MA (US); Matthew J. Hawryluk, Newton, MA (US); Doron Lipson, Chestnut Hill, MA (US); Alexander N. Parker, Boston, MA (US); and Philip James Stephens, Lexington, MA (US)
Assigned to Foundation Medicine, Inc., Boston, MA (US)
Filed by Foundation Medicine, Inc., Cambridge, MA (US)
Filed on Aug. 4, 2022, as Appl. No. 17/817,619.
Application 15/045,716 is a division of application No. 14/187,280, filed on Feb. 23, 2014, granted, now 9,297,011, issued on Mar. 29, 2016.
Application 17/817,619 is a continuation of application No. 17/588,150, filed on Jan. 28, 2022, abandoned.
Application 17/588,150 is a continuation of application No. 17/482,280, filed on Sep. 22, 2021, abandoned.
Application 17/482,280 is a continuation of application No. 17/166,848, filed on Feb. 3, 2021, abandoned.
Application 17/166,848 is a continuation of application No. 16/900,756, filed on Jun. 12, 2020, abandoned.
Application 16/900,756 is a continuation of application No. 16/691,749, filed on Nov. 22, 2019, abandoned.
Application 16/691,749 is a continuation of application No. 15/839,560, filed on Dec. 12, 2017, abandoned.
Application 15/839,560 is a continuation of application No. 15/045,716, filed on Feb. 17, 2016, granted, now 9,884,060, issued on Feb. 6, 2018.
Application 14/187,280 is a continuation of application No. PCT/US2012/051978, filed on Aug. 23, 2012.
Claims priority of provisional application 61/594,739, filed on Feb. 3, 2012.
Claims priority of provisional application 61/542,112, filed on Sep. 30, 2011.
Claims priority of provisional application 61/537,024, filed on Sep. 20, 2011.
Claims priority of provisional application 61/526,613, filed on Aug. 23, 2011.
Prior Publication US 2023/0241065 A1, Aug. 3, 2023
Int. Cl. A61K 31/517 (2006.01); A61K 31/404 (2006.01); A61K 31/4412 (2006.01); A61K 31/444 (2006.01); A61K 31/47 (2006.01); A61K 31/513 (2006.01); C07K 14/82 (2006.01); C12N 9/14 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01)
CPC A61K 31/517 (2013.01) [A61K 31/404 (2013.01); A61K 31/4412 (2013.01); A61K 31/444 (2013.01); A61K 31/47 (2013.01); A61K 31/513 (2013.01); C07K 14/82 (2013.01); C12N 9/14 (2013.01); C12N 15/1135 (2013.01); C12Q 1/6886 (2013.01); C07K 2319/00 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 26 Claims
 
1. A method of treating a subject having a thyroid cancer, comprising:
responsive to a determinization of the presence of a Kinesin Family Member 5B (KIF5B)-RET fusion polypeptide or a nucleic acid molecule encoding the KIF5B-RET fusion polypeptide, administering to the subject an effective amount of a kinase inhibitor or a RET-specific inhibitor,
wherein the KIF5B-RET fusion polypeptide comprises a RET tyrosine kinase domain, a KIF5B kinesin motor domain, and a KIF5B coiled-coil domain of SEQ ID NO:2.